View all available purchase options and get full access to this article.

ROS1 Rearrangements in Lung Cancer: A New Genomic Subset of Lung Adenocarcinoma Palliative care is frequently misconstrued as synonymous with end-of-life care. Palliative care is focused on the relief ...

The MARIANE-trial: Multicenter phase 1b/2 trial testing safety and efficacy of neoadjuvant intradermal ipilimumab and nivolumab in high-risk stage II melanoma. This is an ASCO Meeting Abstract from ...

For patients with early-stage breast cancer, predicting the risk of metastatic relapse is of crucial importance. Existing predictive models rely on agnostic survival analysis statistical tools (eg, ...

Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers. Safety and clinical activity of MEDI5752, a PD-1/CTLA-4 bispecific checkpoint ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family ...

Pattern of granulocyte colony stimulating growth factors (G-CSGF) usage in patients treated with sacituzumab govitecan: A real world multicenter study using the TriNetX database. This is an ASCO ...

Analysis of a prospectively collected clinical database was performed. We included 1,118 patients who received neoadjuvant chemotherapy at M.D. Anderson Cancer Center for stage I-III breast cancer ...

NRG Oncology/RTOG 0848: Results after adjuvant chemotherapy +/- chemoradiation for patients with resected periampullary pancreatic adenocarcinoma (PA). This is an ASCO Meeting Abstract from the 2024 ...

Glioblastoma (GBM) is a rare tumor and one of the most challenging malignancies to treat in all of oncology. Although advances have been made in the treatment of GBM, encouraging outcomes typically ...

Linvoseltamab (LINVO) + carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial results from the LINKER-MM2 trial.

Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely ...